Literature DB >> 15305163

Sentinel node biopsy procedures with an analysis of recurrence patterns and prognosis in melanoma patients: technical advantages using computer-assisted gamma probe with adjustable collimation.

Lorenzo Borgognoni1, Carmelo Urso, Luca Vaggelli, Paola Brandani, Gianni Gerlini, Umberto Maria Reali.   

Abstract

The purpose of this study was to investigate whether a computer-assisted gamma probe with adjustable collimation could aid in the detection of sentinel nodes (SNs) and to analyse the patterns of recurrence and prognosis in SN-positive and SN-negative cases. We analysed 385 SN biopsies. The SN identification rate was 87.2% using preoperative lymphoscintigraphy and blue dye, 93.9% using preoperative lymphoscintigraphy, blue dye and different probes, and 100% using preoperative lymphoscintigraphy, blue dye and a computer-assisted probe with adjustable collimation. The computer-assisted probe was particularly advantageous in cases where the melanoma was located very close to the SN and in cases of deep-seated nodes or nodes with low uptake, due to the possibility of changing the collimation during the procedure. The SN-positive rate according to the thickness of the primary melanoma was 1.7% for melanomas < or = 1 mm in thickness and 27.5% for melanomas > or = 1 mm. In 4.9% of cases we identified nodes outside the regional nodal basin. In one case we found a micrometastasis in a blue and hot interval node of the lateral abdominal wall. Analysing the node counts registered by the computer-assisted probe, we verified that the blue-positive node for tumour metastases was not the most radioactive node in the field in six out of 52 positive cases (11.5%). Distant metastases were present in 2.0% of SN-negative patients, and in 24% of SN-positive patients (P < 0.001). Highly statistically significant differences were found between SN-negative and SN-positive patients in both the 3 year disease-free survival (86.3% versus 49.2%) and the 3 year disease-specific survival (92.3% versus 77.1%) (P < 0.001). Copyright 2004 Lippincott Williams & Wilkins

Entities:  

Mesh:

Year:  2004        PMID: 15305163     DOI: 10.1097/01.cmr.0000133968.28172.6e

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  5 in total

1.  Meta-analysis of sentinel lymph node positivity in thin melanoma (<or=1 mm).

Authors:  Melanie A Warycha; Jan Zakrzewski; Quanhong Ni; Richard L Shapiro; Russell S Berman; Anna C Pavlick; David Polsky; Madhu Mazumdar; Iman Osman
Journal:  Cancer       Date:  2009-02-15       Impact factor: 6.860

2.  High Antigen Processing Machinery component expression in Langerhans cells from melanoma patients' sentinel lymph nodes.

Authors:  Maria Raffaella Romoli; Paola Di Gennaro; Gianni Gerlini; Serena Sestini; Paola Brandani; Soldano Ferrone; Lorenzo Borgognoni
Journal:  Cell Immunol       Date:  2017-08-30       Impact factor: 4.868

3.  Tolerogenic IDO1+CD83- Langerhans Cells in Sentinel Lymph Nodes of Patients with Melanoma.

Authors:  Gianni Gerlini; Paola Di Gennaro; Nicola Pimpinelli; Serena Sestini; Lorenzo Borgognoni
Journal:  Int J Mol Sci       Date:  2022-03-22       Impact factor: 5.923

4.  The efficacy of 99mTc-rituximab as a tracer for sentinel lymph node biopsy in cutaneous melanoma patients.

Authors:  Jiayong Liu; Zhichao Tan; Ruifeng Xue; Zhengfu Fan; Chujie Bai; Shu Li; Tian Gao; Lu Zhang; Zhiwei Fang; Lu Si
Journal:  Ann Transl Med       Date:  2022-01

5.  Predictive Values of Pathological and Clinical Risk Factors for Positivity of Sentinel Lymph Node Biopsy in Thin Melanoma: A Systematic Review and Meta-Analysis.

Authors:  Hanzi Huang; Ziyao Fu; Jiang Ji; Jiuzuo Huang; Xiao Long
Journal:  Front Oncol       Date:  2022-01-27       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.